News

Conference Insider

Experts Investigate Value of Chromosomal Complexity in Imatinib Treatment for High-Risk GIST

06/17/2021

Investigators sought to determine if chromosomal complexity could be used as a biomarker in de-escalation of adjuvant imatinib treatment, presented at the 2021 ASCO Annual Meeting.

Investigators sought to...

06/17/2021

Oncology

Conference Insider

Pimitespib Significantly Improves PFS, OS in Patients with Advanced GIST

06/15/2021

A phase III trial evaluated the efficacy and safety of pimitesib in patients with advanced GIST refractory to standard treatments, whose medical requirements remain unmet, presented at the 2021 ASCO Annual Meeting.

A phase III trial evaluated the...

06/15/2021

Oncology

News

Ripretinib Shows Promise In Patients with Refractory Advanced GIST

03/24/2021

Results of a phase 1 trial indicate ripretinib may be a beneficial treatment option for patients with refractory advanced GIST.

Results of a phase 1 trial...

03/24/2021

Oncology

News

Prolonged Adjuvant Imatinib Therapy Tied to Extended OS in High-Risk GIST

02/10/2021

Prolonged adjuvant imatinib for high-risk GIST led to a superior OS over shorter-term imatinib treatment, according to a trial comparing 3- and 1-year regimens.

Prolonged adjuvant imatinib for...

02/10/2021

Oncology

News

Investigational MKIs Improve Outcomes in Metastatic GIST

01/25/2021

Using first-line multi-kinase inhibitors (MKIs) aside from imatinib did not lead to early resistance or decreased efficacy of second-line therapy for metastatic GIST.

Using first-line multi-kinase...

01/25/2021

Oncology

News

Clinical Differences May Exist in Multiple vs Single GISTs

01/21/2021

A retrospective analysis suggests that the clinical features and treatment approaches for multiple GISTs may differ from single GISTs, presenting a gap in the treatment landscape.

A retrospective analysis...

01/21/2021

Oncology

News

Axitinib Plus Octreotide Acetate Safe, Active for Grade 1/2 Gastric NETs

01/19/2021

Axitinib in combination with octreotide acetate showed activity and tolerable safety in patients with G1-G2 NETS of non-pancreatic origin.

Axitinib in combination with...

01/19/2021

Oncology

News

Surgery Plus Systemic Therapy Improves Outcomes in Stage IV GIST

01/14/2021

A study evaluating treatment methods of stage IV GIST found surgery in combination with systemic therapy demonstrates the best outcomes for patients.

A study evaluating treatment...

01/14/2021

Oncology

News

Follow-Up INVICTUS Trial Data Show Improved OS With Ripretinib for GIST

10/16/2020

OS improved for patients with advanced GIST treated with ripretinib, according to follow-up study findings presented at the 2020 Virtual ESMO Annual Meeting.

OS improved for patients with...

10/16/2020

Oncology

News

Microscopically Positive Resection Margin Has No Influence on OS, RFS in GIST

09/14/2020

R1 margins did not significantly influence OS and RFS after resection compared with R0 margins in patients with GIST, according to results from a retrospective study.

R1 margins did not significantly...

09/14/2020

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology